Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Transposon Implicated As Colon Cancer Trigger

XTALKS VITALS NEWS

Colon Cancer

Using new technologies allowing them to track insertion of the L1 transposon, the researchers found that the L1 transposon affects a tumor suppressor gene known as APC. This gene has been shown to be mutated in approximately 85 percent of colorectal cancers.

Share this!

May 13, 2016 | by Sarah Massey, M.Sc.

Transposons – genes that are able to extricate themselves from one part of the genome, and insert into another location – could play a role in colon cancer development, according to research performed at the University Of Maryland School Of Medicine in Baltimore. While a surprising number of these so-called “jumping genes” are present in the human genome, little is known about their function.

Transposons were first discovered in maize in the 1940s by geneticist, Barbara McClintock. These transposable elements are responsible for some of the colour variation seen in maize kernels, and McClintock would later go on to win the Nobel Prize for her discovery.

While previous research showed that transposons were active in many types of cancer, this is the first time they have been conclusively linked to development of the disease. The research was published in the journal, Genome Research.

The study authors researched a transposon known as L1, which was previously thought to have no effect. In the last 25 years, however, multiple studies have shown that the transposon is active in disease states, including hemophilia and some cancers.

Using new technologies allowing them to track insertion of the L1 transposon, Dr. Scott E. Devine, associate professor of medicine at the University Of Maryland School Of Medicine in Baltimore, and his colleagues found that L1 affects a tumor suppressor gene known as APC. This gene has been shown to be mutated in approximately 85 percent of colorectal cancers.

To figure out how common L1 insertions were among patients with colorectal cancer, the team screened tumor samples taken from ten patients. Evidence of L1 insertions in the APC gene were found in nine of the ten tumor samples, and no evidence of this phenomenon was seen in healthy tissue.

According to the researchers, just one L1 insertion is sufficient to inactivate the APC tumor suppressor gene, allowing tumors to grow unchecked. This L1 insertion also pairs up with a mutation in a patient’s second copy of the APC gene, effectively silencing the gene’s role in preventing cancer.

“This is really a new way to understand how tumors grow,” said Devine. “We think it could explain a lot about the mutation process that underlies at least some cancers.”



As some of the patients tested had a familial history of cancer, Devine suggests that some groups could be more susceptible to cancers resulting from L1 insertions. Interestingly, as over half of our genome is made up of transposons and other mobile DNA elements, it’s likely they also play a crucial role in normal cell functions.


Keywords: Colon Cancer, Tumor Suppression, Human Genome


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.